Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Di Bartolomeo · SciRah

Researcher profile · Semantic Scholar

M. Di Bartolomeo

Share profile

M. Di Bartolomeo — researcher profile on SciRah

h-index: 58
Works: 394
Citations: 14K

Most-cited papers

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
Y. Doki, J. Ajani, Ken Kato, Jianming Xu +26 more
2022New England Journal of Medicine916 citations Open access
Semantic Scholar
Predictive role of microsatellite instability for of PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials
F. Pietrantonio, G. Randon, M. Di Bartolomeo, A. Luciani +3 more
2021ESMO Open158 citations Open access
Semantic Scholar
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
T. Yoshino, M. Di Bartolomeo, K. Raghav, T. Masuishi +16 more
2023Nature Communications155 citations Open access
Semantic Scholar
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
C. Fuchs, M. Özgüroğlu, Y. Bang, M. Di Bartolomeo +16 more
2021Gastric Cancer147 citations Open access
Semantic Scholar
Trastuzumab deruxtecan in Western patients with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen: results from a phase 2, single-arm study
E. Van Cutsem, M. Di Bartolomeo, E. Smyth, I. Chau +12 more
2023The Lancet Oncology128 citations Open access
Semantic Scholar
NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer
F. Nichetti, S. Rota, P. Ambrosini, C. Pircher +12 more
2024JAMA Network Open126 citations Open access
Semantic Scholar
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial
F. Morano, A. Raimondi, F. Pagani, S. Lonardi +29 more
2022Journal of Clinical Oncology104 citations Open access
Semantic Scholar
Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO.
A. Raimondi, S. Lonardi, S. Murgioni, G. G. Cardellino +46 more
2024Annals of Oncology99 citations Open access
Semantic Scholar
INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC).
F. Pietrantonio, A. Raimondi, S. Lonardi, S. Murgioni +16 more
2023Journal of Clinical Oncology80 citations Open access
Semantic Scholar
Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.
I. Chau, Y. Doki, J. Ajani, Jian-Ming Xu +16 more
202175 citations
Semantic Scholar
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial
K. Kato, Y. Doki, I. Chau, Jianming Xu +18 more
2024Cancer Medicine67 citations Open access
Semantic Scholar
Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors
S. Pusceddu, N. Prinzi, S. Tafuto, T. Ibrahim +53 more
2022JAMA Network Open58 citations Open access
Semantic Scholar
Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase 3 trial in patients with gastroesophageal adenocarcinoma.
K. Shitara, M. Özgüroğlu, Y. Bang, M. Di Bartolomeo +14 more
2021Annals of Oncology58 citations Open access
Semantic Scholar
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.
K. Raghav, S. Siena, A. Takashima, T. Kato +16 more
2023Journal of Clinical Oncology55 citations Open access
Semantic Scholar
TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study
A. Raimondi, Federica Palermo, M. Prisciandaro, M. Aglietta +28 more
2021Cancers50 citations Open access
Semantic Scholar
Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial
E. Grassi, C. Zingaretti, E. Petracci, J. Corbelli +18 more
2023ESMO Open44 citations Open access
Semantic Scholar
LBA55 Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen
E. Van Cutsem, M. Di Bartolomeo, E. Smyth, I. Chau +12 more
2021Annals of Oncology44 citations Open access
Semantic Scholar
Nutritional Support Indications in Gastroesophageal Cancer Patients: From Perioperative to Palliative Systemic Therapy. A Comprehensive Review of the Last Decade
G. Mulazzani, F. Corti, S. Della Valle, M. Di Bartolomeo
2021Nutrients43 citations Open access
Semantic Scholar
Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.
Y. Janjigian, D. Oh, S. Rha, Keun-Wook Lee +10 more
2022Journal of Clinical Oncology38 citations Open access
Semantic Scholar
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).
T. Yoshino, M. Di Bartolomeo, K. Raghav, T. Masuishi +16 more
202137 citations
Semantic Scholar
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01
S. Siena, K. Raghav, T. Masuishi, K. Yamaguchi +15 more
2024Nature Communications34 citations Open access
Semantic Scholar
LBA74 Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-585 study
K. Shitara, S. Rha, L. Wyrwicz, T. Oshima +15 more
2023Annals of Oncology33 citations
Semantic Scholar
1205MO Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen
G. Ku, M. Di Bartolomeo, E. Smyth, I. Chau +12 more
2022Annals of Oncology33 citations Open access
Semantic Scholar
Preferred neoadjuvant therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis
G. Grizzi, F. Petrelli, M. Di Bartolomeo, M. Viti +7 more
2022Gastric Cancer29 citations Open access
Semantic Scholar
Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
G. Fucà, F. Corti, M. Ambrosini, R. Intini +20 more
2021Journal for ImmunoTherapy of Cancer29 citations Open access
Semantic Scholar
ALK Inhibitors in Patients With ALK Fusion–Positive GI Cancers: An International Data Set and a Molecular Case Series
M. Ambrosini, M. Del Re, P. Manca, A. Hendifar +17 more
2022JCO Precision Oncology28 citations Open access
Semantic Scholar
International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape
P. Morgagni, M. Bencivenga, F. Carneiro, S. Cascinu +34 more
2024Gastric Cancer27 citations Open access
Semantic Scholar
Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial
K. Shitara, M. Di Bartolomeo, M. Mandalà, M. Ryu +15 more
2023Journal for ImmunoTherapy of Cancer24 citations Open access
Semantic Scholar
HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
F. Pietrantonio, P. Manca, S. Bellomo, S. Corso +13 more
2022Clinical Cancer Research24 citations Open access
Semantic Scholar
Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer
L. Castagnoli, S. Corso, Alma Franceschini, A. Raimondi +13 more
2023Cellular Oncology23 citations Open access
Semantic Scholar
Anti-tumor activity of all-trans retinoic acid in gastric-cancer: gene-networks and molecular mechanisms
L. Guarrera, M. Kurosaki, S. Garattini, M. Giannı́ +12 more
2023Journal of experimental & clinical cancer research : CR22 citations Open access
Semantic Scholar
Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients-A pooled analysis of three adjuvant trials.
N. Christou, E. Bergen, C. Canton, K. Le Malicot +10 more
2022European Journal of Cancer21 citations Open access
Semantic Scholar
Impact of Surgical Margins on Overall Survival after Gastrectomy for Gastric Cancer: A Validation of Japanese Gastric Cancer Association Guidelines on a Western Series
Marianna Maspero, C. Sposito, Antonio Benedetti, M. Virdis +3 more
2022Annals of Surgical Oncology21 citations Open access
Semantic Scholar
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study
M. Niger, F. Nichetti, L. Fornaro, C. Pircher +33 more
2024BMC Cancer20 citations Open access
Semantic Scholar
Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study
S. Pusceddu, C. Vernieri, M. di Maio, N. Prinzi +10 more
2021Cancers20 citations Open access
Semantic Scholar
386O Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC)
S. Siena, K. Raghav, T. Masuishi, K. Yamaguchi +14 more
2021Annals of Oncology19 citations Open access
Semantic Scholar
Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study
A. Raimondi, G. Fucà, A. Leone, S. Lonardi +15 more
2021ESMO Open19 citations Open access
Semantic Scholar
The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer
P. Manca, S. Corallo, A. Busico, S. Lonardi +21 more
2021Clinical Cancer Research19 citations Open access
Semantic Scholar
Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial
Yoon-Koo Kang, M. Ryu, M. Di Bartolomeo, I. Chau +14 more
2024Gastric Cancer18 citations Open access
Semantic Scholar
Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas
S. Corso, F. Pietrantonio, M. Apicella, C. Migliore +38 more
2021Clinical Cancer Research18 citations Open access
Semantic Scholar
Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial
F. Corti, M. P. Brizzi, V. Amoroso, D. Giuffrida +17 more
2023BMC Cancer16 citations Open access
Semantic Scholar
Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective
M. Prisciandaro, M. Antista, A. Raimondi, F. Corti +15 more
2022Frontiers in Oncology16 citations Open access
Semantic Scholar
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial.
G. Rosati, S. Lonardi, F. Galli, M. Di Bartolomeo +23 more
2021European Journal of Cancer15 citations
Semantic Scholar
Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial.
G. Randon, S. Lonardi, M. Fassan, F. Palermo +28 more
2024The Lancet Oncology13 citations
Semantic Scholar
LBA3 Final analysis of the phase III KEYNOTE-585 study of pembrolizumab plus chemotherapy vs chemotherapy as perioperative therapy in locally-advanced gastric and gastroesophageal junction cancer
K. Shitara, S. Rha, L. Wyrwicz, T. Oshima +15 more
2024Annals of Oncology12 citations
Semantic Scholar
SO-7 Co-occurring HER2 and PD-L1 expression in patients with HER2-positive trastuzumab-refractory gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): Biomarker analysis from the trastuzumab deruxtecan (T-DXd) DESTINY-Gastric03 trial
Y. Janjigian, S. Rha, D. Oh, M. D. García +8 more
2022Annals of Oncology12 citations Open access
Semantic Scholar
Early onset metastatic colorectal cancer in patients receiving panitumumab‐based upfront strategy: Overall and sex‐specific outcomes in the Valentino trial
A. Raimondi, G. Randon, M. Prisciandaro, F. Pagani +19 more
2022International Journal of Cancer12 citations
Semantic Scholar
Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648.
I. Chau, J. Ajani, Y. Doki, Jianming Xu +16 more
2022Journal of Clinical Oncology11 citations
Semantic Scholar
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS / BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis
F. Pietrantonio, G. Fucà, D. Rossini, Hans +19 more
202111 citations
Semantic Scholar
Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer.
A. Zaniboni, C. Barone, M. Banzi, F. Bergamo +16 more
2021Future Oncology10 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

F. Pietrantonio×18
Invite
F. Pietrantonio — researcher profile on SciRah
S. Lonardi×14
Invite
S. Lonardi — researcher profile on SciRah
F. Morano×14
Invite
F. Morano — researcher profile on SciRah
A. Raimondi×11
Invite
A. Raimondi — researcher profile on SciRah

M. Prisciandaro

×11

Invite

M. Prisciandaro — researcher profile on SciRah

Invite

G. Randon — researcher profile on SciRah

Invite

H. Kawakami — researcher profile on SciRah

Invite

F. De Braud — researcher profile on SciRah

Invite

F. Corti — researcher profile on SciRah

Invite

I. Chau — researcher profile on SciRah

Invite

M. Niger — researcher profile on SciRah

Invite

M. di Maio — researcher profile on SciRah